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Introduction: Triple-negative breast cancer (TNBC) patients often face a high risk of early relapse characterized by
extensive metastasis. Previous works have shown that aberrant cell surface glycosylation is associated with cancer
metastasis, suggesting that altered glycosylations might serve as diagnostic signatures of metastatic potential. To
address this question, we took TNBC as an example and analyzed six TNBC cell lines, derived from a common
progenitor, that differ in metastatic potential.
Methods: We used a microarray with 91 lectins to screen for altered lectin bindings to the six TNBC cell lines.
Candidate lectins were then verified by lectin-based flow cytometry and immunofluorescent staining assays using
both TNBC/non-TNBC cancer cells. Patient-derived tissue microarrays were then employed to analyze whether the
staining of Ricinus communis agglutinin I (RCA-I), correlated with TNBC severity. We also carried out real-time cell
motility assays in the presence of RCA-I. Finally, liquid chromatography-mass spectrometry/tandem spectrometry
(LC-MS/MS) was employed to identify the membrane glycoproteins recognized by RCA-I.
Results: Using the lectin microarray, we found that the bindings of RCA-I to TNBC cells are proportional to their
metastatic capacity. Tissue microarray experiments showed that the intensity of RCA-I staining is positively correlated
with the TNM grades. The real-time cell motility assays clearly demonstrated RCA-I inhibition of adhesion, migration,
and invasion of TNBC cells of high metastatic capacity. Additionally, a membrane glycoprotein, POTE ankyrin domain
family member F (POTEF), with different galactosylation extents in high/low metastatic TNBC cells was identified by
LC-MS/MS as a binder of RCA-I.
Conclusions: We discovered RCA-I, which bound to TNBC cells to a degree that is proportional to their metastatic
capacities, and found that this binding inhibits the cell invasion, migration, and adhesion, and identified a membrane
protein, POTEF, which may play a key role in mediating these effects. These results thus indicate that RCA-I-specific cell
surface glycoproteins may play a critical role in TNBC metastasis and that the extent of RCA-I cell binding could be used
in diagnosis to predict the likelihood of developing metastases in TNBC patients.* Correspondence: ericgao168@gmail.com; xfhu@sjtu.edu.cn; taosc@sjtu.edu.cn
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Breast cancer is the leading cause of death from cancer
in women and indeed one of the most prevalent types
of cancers worldwide [1]. Triple-negative breast cancer
(TNBC) accounts for 15 to 20% of all breast cancers and
is associated with the worst prognosis [2]. TNBC is char-
acterized by a lack of estrogen receptor/progesterone re-
ceptor (ER/PgR) expression and an absence of human
epidermal growth factor receptor 2 (HER2) overexpres-
sion or amplification, which makes it insensitive to hor-
mone or trastuzumab treatment [3]. As such, the most
common current treatment option for TNBC patients is
cytotoxic chemotherapy [4]. Yet with this, even for pa-
tients who at first respond well to therapy, there is a
high rate of early relapse [5] and a poor long-term out-
come [6]. Moreover, there is presently no effective treat-
ment for TNBC patients with many metastatic niches
[7]. Hence, with such a poor prognosis and tendency to
relapse with distant metastases, there is an urgent med-
ical need to understand the mechanisms underlying me-
tastasis in TNBC to develop better therapy and methods
of early diagnosis.
Recently, many studies have found that the occurrence
or progression of a number of different tumors is associ-
ated with aberrant protein glycosylation. For example, un-
usual sialylation and fucosylation [8], increased branching
of N-glycans [9], and truncated O-glycans [10] have all
been observed in tumors and correlated with tumor devel-
opment. Altered glycans on cell surfaces have also recently
been implicated in the development of metastases [11].
For example, core-3-derived glycans were reported to be
downregulated in metastatic pancreatic cancer [12] and a
global decrease in larger branched tri-and tetra-antennary
N-linked glycans was found to be correlated with the pro-
gression of prostate cancer [13]. Yet a thorough under-
standing of the changes in cell surface glycans during the
progression of cancer requires techniques capable of pro-
filing and analyzing an entire cell surface repertoire of gly-
cans. Lectin (sugar-binding protein) microarrays have
recently emerged as a significantly promising technology
for obtaining such whole-cell glycan characterizations in a
very rapid fashion [14,15]. With nearly 100 different
arrayed lectins, such highly multiplexed characterization
enables the possibility for the detection of fine differences
between cells and the identification of specific lectins re-
sponsible for these differences, which may then be ex-
plored in diagnostic applications [14].
In the present study, a high-density lectin microarray
containing 91 lectins was used to compare the cell sur-
face glycan patterns of a TNBC cell line (MDA-MB-231)
and five other cell lines of different metastatic potential
that are derived from this cell line [16]. Surprisingly, we
found that a single terminal galactose-specific lectin,
Ricinus communis agglutinin I (RCA-I), binds to thesecells to a degree that is proportional to their metastatic
capacity. This result was confirmed in RCA-I binding
experiments using TNBC patient-derived tissue microar-
rays, where greater binding was observed to later-stage
tumors with high metastatic capacity [17]. By compari-
son, there was no correlation between the extent of
RCA-I binding and the clinical stage of non-TNBC tis-
sue. Moreover, somewhat unexpectedly, we also found
that RCA-I specifically blocked the adhesion, invasion,
and migration of the cell lines with greater metastatic
potential. In addition, using LC-MS/MS and stable iso-
tope labeling by amino acids in cell culture (SILAC), we
identified a membrane glycoprotein, POTE ankyrin do-
main family member F (POTEF), showing different ex-
tents of galactosylation in high versus low metastatic
TNBC cells. Overall, these results point to a role of RCA-
I-specific membrane glycans in TNBC metastasis and, im-
portantly, identify RCA-I as a potential diagnostic or
therapeutic agent of this presently poorly treated cancer.
Methods
Chemicals and reagents
All of the lectins were purchased from EY Laboratories
(San Mateo, CA, USA) or Vector Laboratories (Burlingame,
CA, USA) unless otherwise indicated. All the cell culture
media and serum were from Life Technologies (Carlsbad,
CA, USA) unless otherwise indicated. Carboxyfluorescein
diacetate succinimidyl ester (CFDA-SE) was also from Life
Technologies (Carlsbad, CA, USA). Cy3-streptavidin and
paraformaldehyde (PFA) were from Sigma-Aldrich China
(Shanghai, China). DAPI was from Roche Diagnostics
(Mannheim, Germany).
Cell cultures
The MBA-MD-231 cell line and five other descendant
cell lines (SCP2, SCP4, SCP6, SCP28 and 4175) were
kindly provided by Professor Yinbin Kang of Princeton
University. Other breast cancer lines (MCF7, SKBR3,
BT549 and SUM159) were from American Type Culture
Collection (ATCC, Manassas, VA, USA) or China Center
for Type Culture Collection, (CCTCC, Wuhan Univer-
sity, Wuhan, China). MBA-MD-231, SCP2, SCP4, SCP6,
SCP28, 4175 and MCF7 were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) with 10% fetal bovine
serum (FBS); BT549 was cultured in PRIM01640 with
10% FBS; SKBR3 was cultured in McCoy’s 5A with 10%
FBS; SUM159 was cultured in F12K with 10% FBS. All
cell lines were passaged every 2 to 3 days when the cell
confluence reached about 80%.
Lectin microarray screening for surface glycans on live
cells
The fabrication of the lectin microarray and profiling of
live cells was performed as previously described [14].
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fluorescently labeled with CFDA-SE. The cells were then
resuspended in binding buffer (phosphate-buffered sa-
line (PBS) with 0.5 mM CaCl2, 0.1 mM MnCl2 and 1%
bovine serum albumin (BSA)) and 5 × 105 cells were
probed per block on the lectin microarray. After incuba-
tion for 1 hr at room temperature, the microarray was
washed in PBST (PBS with 0.5% Tween-20). The bound
cells were detected by a GenePix 4200A scanner and the
fluorescence intensity of each spot was measured with
GenePix Pro 6.0 Software (Molecular Devices, Sunnyvale,
CA, USA). Lectins that displayed signal intensities of
greater than or equal to three standard deviations above
background were defined as positive signals.
Flow cytometry (FCM) analysis of lectin-cell binding
We followed a protocol slightly modified from that pre-
viously described [18]. Briefly, 1 × 105 cells of each cell
line were resuspended in serum-free medium and incu-
bated with 50 μg/ml of biotinylated lectin for 15 min at
18°C. The cells were then washed three times with PBS
and incubated with Cy3-streptavidin at 1 μg/ml. After
three washes, cells were resuspended in FACS Flow (BD
Biosciences, Franklin Lakes, NJ, USA) supplemented
with 0.1% BSA and analyzed in a FacsCalibur™ flow cyt-
ometer (BD Biosciences, Franklin Lakes, NJ, USA) using
CellQuest software (BD Biosciences, Franklin Lakes, NJ,
USA), following a standard protocol.
Lectin staining assay
This assay was carried out as described [19]. Briefly, cells
cultured in 24-well plates were fixed with 4% PFA for
30 min on ice. The fixed cells were then incubated with
biotinylated lectin at 50 μg/ml for 1 hr at room tem-
perature, followed by incubation with Cy3-conjugated
streptavidin. DAPI staining was also carried out on the
same sample. The results were analyzed by microscopy
(DMI6000B, Leica, Jena, Germany).
Transwell assays for cell invasion
This assay was performed as previously described [20]
with slight modification. Briefly, cells were starved in
serum-free medium for 20 hr. Single-cell suspensions
were then prepared in serum-free medium and incu-
bated with RCA-I at concentrations of 0, 1, 2.5 and
5 μg/ml. The pre-blocked cells were resuspended and
added to the upper chamber of matrigel-coated inserts
with an 8-μm pore polycarbonate membrane in a 24-
well transwell plate (Corning Costar Corp., Cambridge,
MA, USA). The cells were allowed to invade toward
medium containing 10% FBS in the lower chambers.
After 20 hr incubation, cells on the upper surface of the
membrane were wiped off with a cotton swab, and the
cells that had migrated below the membrane werestained with CFDA-SE, and examined using fluorescence
microscopy.Real-time cell analyzer (RTCA) assays for cell adhesion,
migration and invasion
Experiments were carried out using the xCELLigence
RTCA DP (Roche Diagnostics GmbH, Mannheim,
Germany) as described [21]. For the migration and inva-
sion assays, a CIM-16 plate (Roche Diagnostics GmbH,
Mannheim, Germany) was used with (for invasion) or
without (for migration) matrigel coating. The cells were
first incubated with RCA-I at various concentrations and
resuspended in 100 μl serum-free medium. The cells (4 ×
104 per well) were then seeded into each well of the upper
chamber of the CIM-16 plate. For the invasion assay, the
cells were incubated for about 24 hr in a cell incubator
and the cell index (CI) was monitored every 5 min. The
CI is linearly related to the number of cells [21]. Four rep-
licates of each cell concentration were used in each test.
For the migration experiments, the whole process was simi-
lar, but the incubation time was much shorter (approxi-
mately 12 hr). For the adhesion assay, an E-plate 16-well
plate (Roche Diagnostics GmbH, Mannheim, Germany)
was used and the whole process was similar to that for the
analysis of cell proliferation [22]. The CI was monitored
every 1 min for about 1 hr. Four replicates of each cell
concentration were carried out in each test.Tissue microarray analysis
The TNBC tissue microarray containing 52 TNBC clinic
samples of different TNM grades and breast cancer tis-
sue microarray of all types with survival time containing
160 clinic samples were purchased from Shanghai Outdo
Biotech Company (Shanghai, China). Shanghai Outdo
Biotech Company is a daughter company of Shanghai
Biochip Co., Ltd., which is also the National Engineering
Center for Biochip Design and Engineering in Shanghai.
The tissue samples on the tissue microarrays that we
used in this study were collected from Tai Zhou hospital
of Zhejiang province, China. All the patients had been
given informed consent and the collection of tissue sam-
ples for research was approved by the ethics committee
of Tai Zhou hospital. The immunohistochemistry (IHC)
assay using RCA-I was performed as described [23].
Briefly, the slides were first deparaffinized, followed by
blocking with 30% normal donkey serum. Biotinylated
lectin was then added onto the slide (50 μg/ml) and in-
cubated for 1 hr, followed by incubation with horserad-
ish peroxidase (HRP)-conjugated streptavidin and the
signal was visualized by using a DAB protein kit (Sigma-
Aldrich China Inc., Shanghai, China). The specimens
were analyzed under a light microscope (Nikon, Tokyo,
Japan) by pathologists.
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ratio of positive cells to total cancer cells, and a value of
10% or higher was defined as a positive signal [2]. In
addition, RCA-I staining intensity was defined from 0 to
4 based on the color shades of IHC staining. Statistical
analysis was performed by GraphPad Prism 5.0 (Graph-
Pad Software Inc., San Diego, CA, USA).
SILAC labeling and membrane protein extraction
TNBC cell lines SCP6 were cultured in DMEM contain-
ing heavy 13C-labeled lysine supplemented with dialyzed
FBS (Pierce, Rockford, IL, USA) while 4175 cells were
cultured in DMEM containing light (12C) lysine for a
minimum of six population doublings as described in
reference [24]. Membrane protein extraction was per-
formed using the Mem-PER Kit (Pierce, Rockford, IL,
USA) with protease cocktail inhibitors (Roche Diagnos-
tics GmbH, Mannheim, Germany) according to standard
procedures.
Capture of membrane glycoproteins by RCA-I affinity
Biotinylated RCA-I was immobilized onto streptavidin
magnetic beads (Invitrogen, Carlsbad, CA, USA) as de-
scribed in reference [25]. Glycoprotein capture was per-
formed as in reference [26]. Briefly, cell lysate containing
800 μg protein extracted from 13C-labeled SCP6 cells
and 12C-labeled 4175 cells each were mixed at a 1:1 ratio
and diluted four times with binding buffer (20 mM Tris-
HCl, pH7.4, 150 mM NaCl, 1 mM MgCl2, 1 mM CaCl2,
and 1 mM MnCl2). The lysate mixture was then incu-
bated with RCA-I-coated magnetic beads for 2 hr at 4°C
to capture the membrane glycoproteins and the captured
glycoproteins were released with 100 μL elution buffer
(200 mM D-galactose in binding buffer, pH 7.4).
Liquid chromatography-mass spectrometry/tandem
spectrometry (LC-MS/MS) and data analysis
For LC-MS/MS, the assay was performed as described
in reference [26] with modifications. In brief, about
1.5 mg of total protein was separated by 12% SDS-PAGE
gel and was cut into bands and then diced into 1 cm3
cubes. In-gel trypsin digestion was done according to
standard procedures [27]. Peptide samples were then an-
alyzed using a high-throughput electrospray ion-trap
mass spectrometer amaZon ETD (Bruker Daltonics,
Bremen, Germany) combined with an Ultimate™ 3000
Nano-LC system (Dionex, Sunnyvale, CA, USA). Mass
spectra were recorded in the stand-enhanced mode at a
speed of 8,100 m/z. Tandem mass spectra were acquired
in the ultra-scan operating mode at 26,000 m/z/s
(Bruker Esquire Control software, Bruker Daltonics,
Bremen, Germany). The raw files were processed using the
LC/MS software DataAnalysis 4.0 (Bruker Compass soft-
ware, Bruker Daltonics, Bremen, Germany) and convertedinto mgf files for MASCOT 2.3 (Matrix Science, Boston,
MA, USA) evaluation using a forward and reverse human
protein database from International Protein Index (IPI).
Results
Metastasis-specific lectin binding identified on TNBC cell
lines
Six TNBC cell lines (SCP4, SCP6, MDA-MB-231, SCP28,
SCP2 and 4175) that differ in metastatic capacity were
chosen in this study owing to their common origin and
extensive previous characterization [28,29]. To identify
the cell surface glycan profiles associated with each of
these cell lines, freshly harvested cells were first stained by
CFDA-SE and then incubated on a lectin microarray con-
taining 91 lectins, in which each lectin was present in trip-
licate [14] (Figure 1a-c). Overall, we found that these cells
bound between 43 and 49 lectins (Figure S1 in Additional
file 1). Of these, 41 were common among all cell lines,
and, of the remaining, six were common among at least
two cell lines. This high degree of overlap is probably
owing to the fact that these cells were derived from a
common progenitor. Among the lectins that were ob-
served to bind to these cell lines, four (namely, RCA-I,
Triticum vulgaris agglutinin (WGA), Wisteria floribunda
agglutinin (WFA) and Sambucus nigra agglutinin I (SNA-I))
were found to show noticeably different extents of binding
to different cell lines (Figure 1d). Of note, the binding of
RCA-I (a protein found in the plant, Ricinus communis) to
these cell lines was proportional to their metastatic cap-
acity, while that of WGA was inversely proportional. Sur-
prisingly, SNA-I, which was previously reported to show
an enhanced binding to highly metastatic cancer cells [30]
did not exhibit stronger binding to the TNBC cells of
greater metastatic potential, indicating that the sialic acid
content of the surface glycans may not correlate with the
metastatic capacity of these cells. To better compare the
overall lectin-binding profiles of these cells, a heat map
was generated and clustered according to the lectin-
binding pattern and intensity (Figure 1e). Clear differences
in lectin-binding patterns, and thus of the accessible cell
surface glycans, were present between the six cell lines.
Interestingly, the order of the TNBC cell lines in this clus-
ter is the same as the order of their known metastatic cap-
acity, except for the switch in order of the two cell lines
with the highest metastatic potential (4175 and SCP2).
This finding was also observed if the binding patterns of
RCA-I and WGA were excluded from the heat map (data
not shown).
Validation of metastasis-specific lectin-binding patterns in
TNBC and non-TNBC cells
To verify the results from the lectin microarray, represen-
tative interactions were evaluated by lectin-based flow
cytometry, using biotinylated lectins and Cy3-labeled
Figure 1 Identification of metastasis-specific lectin binding to TNBC cells. (a) Schematic of the probing of fluorescently labeled cells on the
lectin microarray. (b) Layout of the lectin microarray containing 91 lectins. (c) Representative lectin microarray binding patterns of the six TNBC
cell lines. (d) Four lectins exhibited different extents of binding to the six different TNBC cell lines. The indicated intensities are represented as the
mean values ± standard deviation (SD), n = 4. (e) Clustered heat map of the lectin cell-binding profiles. This map was generated and clustered
according to the lectin-binding pattern and mean intensity. The order of the cells in this map closely matches their order of metastatic capacity.
TNBC, triple-negative breast cancer.
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representative of three categories: namely, those that
bound proportionally (RCA-I), inversely proportionally
(WGA), or whose binding was uncorrelated with meta-
static capacity (WFA). As summarized in Figure 2a, and
Figure S2a in Additional file 2, we found that the FCM
data indeed exhibited the same binding tendencies as that
of the lectin microarray. To further confirm this result inmore TNBC cells and analyze whether RCA-I binding ex-
hibited a similar tendency in non-TNBC cancer cells, an
additional four breast cancer cell lines (two TNBCs and
two non-TNBCs) were also evaluated with RCA-I-based
FCM. As shown in Figure 2c, RCA-I indeed bound
strongly to these other TNBC cells. Interestingly, RCA-I
also exhibited extensive binding to the non-TNBC cancer
cells.
Figure 2 The RCA-I-binding tendency is constant with the invasion ability of TNBC cells rather than those of non-TNBC cells. (a) FCM
analysis confirms the proportional, inversely proportional, and uncorrelated binding to the metastatic capacity of these cells with RCA-I, WGA, and
WFA, respectively. (b) Incubation of biotinylated RCA-I, WFA, or WGA, followed by the addition of Cy3-conjugated streptavidin and direct inspection
with microscopy further confirmed the cell-binding tendencies of these lectins. (c) The RCA-I-binding positive rates of five TNBC (red) and two
non-TNBC cells (green) were analyzed by FCM, which were referred to their relative metastatic abilities. (d) The immunofluorescent staining of RCA-I
binding to another two TNBC cells (SUM159 and BT549) and two non-TNBC cells (MCF7 and SKBR3). FCM, flow cytometry; RCA-I, Ricinus communis
agglutinin I; TNBC, triple-negative breast cancer; WFA, Wisteria floribunda agglutinin; WGA, Triticum vulgaris agglutinin.
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direct visualization of cells incubated with these biotinyl-
ated lectins followed by Cy3-streptavidin. As shown in
Figure 2b and d, the binding properties from the micro-
array experiments and RCA-I-based FCM assays were
also observed by direct inspection of these labeled cells.
Binding of RCA-I to tissues from TNBC patients
In order to examine the potential clinical relevance of
the observed relationship between membrane RCA-Ibinding and the metastatic capacity of the TNBC cells,
we investigated the extent to which RCA-I binds to
breast cancer tissues of TNBC patients. In particular, we
employed a tissue microarray containing 52 clinical sam-
ples from TNBC patients (median age 52.7 years, range
34 to 79 years, all female) of various TNM grades
(tumor stage range: T1 to T4; node grade range: N0 to
N2). Among these samples, 51 are infiltrating ductal car-
cinoma (IDC) and one is ductal carcinoma in situ (DCIS).
As shown in Figure 3a, membrane-positive staining of
Figure 3 (See legend on next page.)
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Figure 3 Evaluation of RCA-I binding to clinical TNBC samples in a tissue microarray. (a) Overall, a very high proportion of these samples
was bound by RCA-I. There was also a dependence of the rate of positive RCA-I labeling on the clinical stage of the tissue, with later-stage tissues
exhibiting a higher binding rate than early-stage tissues. (b, c) The dependence of the mean intensities and positive rates of RCA-I membrane staining
on the tumor stages. (d, e) The dependence of the mean intensities and positive rates of RCA-I staining on the T and N grades. (f) Representative
views of TNBC tissues of different TNM grades that were incubated with biotinylated RCA-I and Cy3-conjugated streptavidin. RCA-I, Ricinus communis
agglutinin I; TNBC, triple-negative breast cancer.
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showing slightly greater extents at later-stage cancers
(100%) than earlier-stage cancer (87.1%).
In order to determine whether RCA-I binding exhib-
ited any relation to the progression of TNBC in these
tissue samples, we analyzed our findings with respect to
both tumor stage and node grade. As shown in Figure 3b
to e, the intensity and positive rates of RCA-I membrane
staining indeed increased with each of these TNM
grades. However, we note that the RCA-I staining inten-
sities were better correlated with node grades than
tumor stages (Figure 3e and f). It is known that late-
stage cancer exhibits a higher metastatic potential com-
pared to that of early-stage cancer, especially when the
cancer is at a high node grade [31,32]. Thus, overall,
these tissue microarray results are consistent with the
lectin microarray results.
To further analyze whether the binding tendency of
RCA-I is specific in TNBC samples and correlated with
the prognosis of TNBC patients, another tissue micro-
array containing 160 clinical samples (median age
53.1 years, range 29 to 83 years, all female) of different
TNM grades (tumor stage range: T1 to T3; node grade
range: N0 to N3) from both TNBC (n = 29) and non-
TNBC (n = 131) cancer patients with survival information
was evaluated using IHC with RCA-I. As summarized in
Figure 4a, membrane-positive staining of RCA-I was ob-
served in the majority of both TNBC patients (96.6%) and
non-TNBC patients (90.8%).
By comparing the intensities and positive rates of RCA-I
membrane staining in TNBC and non-TNBC clinical sam-
ples, we found that the results from TNBC samples
(Figure 4b and c) were in agreement with those from the
aforementioned TNBC-only tissue microarray (Figure 3b
and c). However, in non-TNBC samples, the intensities
and positive rates of RCA-I membrane staining were quite
similar across all clinical stages and did not show any spe-
cific proportionality (Figure 4e and f). Moreover, a similar
correlation of RCA-I staining intensities with the node
grades of the TNBC samples was also observed as in the
TNBC-only tissue microarray (Figure 4d, and Figure S3,
upper, in Additional file 3), whereas there was no such
correlation in the non-TNBC samples (Figure 3g, and
Figure S3, lower, in Additional file 3).
Using follow-up survival data from the 160 breast can-
cer patients, we stratified the breast-cancer-specificoutcome according to the RCA-I membrane staining in-
tensities. Scoring the RCA-I membrane staining inten-
sities from 0 (low) to 3 (high), we found that indeed the
patients could be stratified into good (RCA-I intensities
ranged from 0 to 0.5), moderate (RCA-I intensities
ranged from 1 to 1.5) and worse prognosis (RCA-I in-
tensities ranged from 2 to 3) in terms of overall survival.
The Kaplan-Meier curves showed a clear difference be-
tween these three groups (Figure 4h). A similar stratifi-
cation was also evaluated with non-TNBC breast cancer
patients, however no significant difference was observed
with the Kaplan-Meier curves with this cohort (Figure 4i).
Taken together, these results clearly indicate that RCA-I
staining intensity shows a high correlation with the N
grades of the TNBC samples, and also with the clinical
outcome of TNBC patients, specifically.
Inhibition of TNBC cell motility by RCA-I
These results thus indicate that the presence of RCA-I-
specific glycans on the cell surface, as judged by the ex-
tent of RCA-I binding, could be a useful indicator of
metastatic potential in diagnostic applications. However,
we also wondered whether the presence of these specific
glycans might contribute to the development of this
metastatic potential. We thus tested whether RCA-I
binding per se affects any processes associated with me-
tastasis. We first evaluated the effects of RCA-I on cell
motility using matrigel-coated transwell assays. We stud-
ied three cell lines that were representative of high, mid-
dle, and low metastatic capacity (4175, SCP28 and SCP6,
respectively). As shown in Figure 5a, the invasion cap-
ability of all three cell lines was inhibited by RCA-I, par-
ticularly at the highest RCA-I concentration. Significant
differences among the three cell lines were, however, ob-
served at lower concentrations of RCA-I. For example,
the invasion rate of 4175 cells was sharply reduced at
1 μg/ml RCA-I while, at this RCA-I concentration, only
a slight inhibition of the invasion rates of SCP6 and
SCP28 cells was observed. This finding suggests that
RCA-I-specific glycans may play a more significant role
in the invasion capacity of those cells with the greatest
metastatic potential. It should be noted that we also per-
formed cell viability and aggregation assays with RCA-I
to rule out the possibility that this lectin may induce ag-
gregation and death of these TNBC cell lines, which may
then contribute to the observed effects. However, as
Figure 4 (See legend on next page.)
Zhou et al. Breast Cancer Research  (2015) 17:36 Page 9 of 14
(See figure on previous page.)
Figure 4 Comparison of RCA-I bindings to clinical TNBC and non-TNBC samples. (a) The summary of all clinical samples showed that there
very high proportions of these samples were bound by RCA-I both in TNBC and non-TNBC samples. (b and c) The dependence of the mean
intensities and positive rates of RCA-I membrane staining on the tumor stages in TNBC, whereas the independence of those in non-TNBC samples
(e and f). (d) The dependence of the mean intensities of RCA-I staining on the T and N grades, whereas the independence of that in non-TNBC
samples (g). (h) Kaplan-Meier survival curves on RCA-I staining intensities in TNBC and non-TNBC samples (i) showed RCA-I-binding intensities
had the statistically significant power to stratify TNBC patients with distinct outcomes. RCA-I, Ricinus communis agglutinin I; TNBC, triple-negative
breast cancer.
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volumes and viabilities of the cell lines incubated with
RCA-I at the same concentrations as that used in the
cell motility assays were not changed appreciably by the
presence of RCA-I.
To obtain a more detailed and dynamic picture of this
RCA-I-dependent inhibition of the motilities of these
cell lines, similar experiments were performed using a
RTCA that monitors the three key processes of tumor
cell motility (namely, adhesion, migration, and invasion)Figure 5 Inhibition of TNBC cell motilities by RCA-I. (a) Transwell assay
using three TNBC cell lines that differed in metastatic capacity. There is a c
(b to m) Cell motility characteristics determined with RTCA. In each figure,
Figure 4b. For the invasion, migration and adhesion assays, the cell index (
adhered cells, respectively. (b to e) Invasion assays, (f to i) migration assay
RTCA, real-time cell analyzer; TNBC, triple-negative breast cancer.in a real-time manner [21]. As shown in Figure 5b-d, the
invasion rate of 4175 was greatly inhibited upon the
addition of RCA-I at concentrations greater than 1.0 μg/ml,
whereas those of SCP6 and SCP28 were only slightly
inhibited compared to the corresponding controls in the
absence of RCA-I (P <0.001). For example, after an incu-
bation of 20 hr with 1.0 μg/ml RCA-I, the invasion rate of
4175 was 12.6% of the rate without added RCA-1, while
those of SCP28 and SCP6 were 47.9% and 50.4%, respect-
ively (Figure 5e).s were performed in the presence of different concentrations of RCA-I
lear dose-dependent inhibition of invasion by RCA-I with each cell line.
the concentration of RCA-I employed is indicated in the inset to
CI) is linearly proportional to the number of invaded, migrated and
s, and (j to m) adhesion assays. RCA-I, Ricinus communis agglutinin I;
Zhou et al. Breast Cancer Research  (2015) 17:36 Page 11 of 14As shown in Figure 5f-i, the results of the migration
assay were similar to those of invasion assay, both in
terms of the effects of RCA-I on different cells and the
RCA-I concentration dependence. Interestingly however,
the results from the adhesion assay were slightly differ-
ent. In particular, as shown in Figure 5j, RCA-I did not
alter the adhesion capability of SCP6 cells, while for
SCP28 and 4175 cells, there was a clear reduction.
As a control, we also investigated the effects of an-
other lectin, WFA, which exhibits similar binding ex-
tents to each of the SCP6, SCP28 and 4175 cells, in
these TNBC cell motility assays. We found that the inva-
sion capabilities of the cell lines were not changed by
the presence of WFA (Figure S5 in Additional file 5).
Hence, the aforementioned effects of RCA-I on TNBC
cell motilities were indeed specific for RCA-I.
Identification of RCA-I-recognized membrane glycoproteins
In order to identify potential RCA-I-specific membrane gly-
coproteins in the TNBC cells, an integrated strategy com-
bining SILAC and LC-MS/MS was employed (Figure 6a).
Comparing the high/low (H/L) ratios of glycoproteins inFigure 6 The identification of RCA-I-recognized membrane glycoprot
combined strategy was used to detect both expression levels and galactosyla
spectrum of a peptide. The sequence of the peptide was identified as VAPEEH
chromatogram of POTEF in the whole-membrane fraction (top) and RCA-I-en
POTEF from 4175 cells whereas the red ones represent those from SCP2 cells
tandem spectrometry; POTEF, POTE ankyrin domain family member F; RCA-I,
acids in cell culture.the RCA-I-enriched fraction with the original whole-
membrane protein fraction, both the changes of expres-
sion levels of target glycoproteins and their extents of
galactosylation can be analyzed simultaneously.
As a result, a poorly characterized protein, prostate,
ovary, testis-expressed POTEF, which belongs to the
POTE membrane protein family, was identified in both
the RCA-I-enriched part and the whole-membrane part
(Figure 6b). It is noteworthy that the relative abundance
of POTEF in the RCA-I-enriched fraction and the
whole-membrane sample was 0.31 and 0.77, respectively
(Figure 6c). Thus, the POTEF captured by RCA-I from
the highly metastatic 4175 cells was about 2.5-fold
greater than that from less metastatic SCP6 cells. Such a
difference is likely owing to a greater extent of accessible
galactose in POTEF in the 4175 cells.
Discussion
Previous studies detailed distinct changes in glycan com-
position associated with the development of both tumors
and metastases [33]. We reasoned that altered cell sur-
face glycosylation might thus have potential in cancerein by SILAC and LC-MS/MS analysis. (a) A SILAC and LC-MS/MS
tions of the membrane glycoproteins captured by RCA-I. (b) LC-MS/MS
PVLLTEAPLNPK, which was from POTEF. (c) Representative base peak
riched membrane fraction (down). The blue lines represent peptides of
(13C-labeled). LC-MS/MS, liquid chromatography-mass spectrometry/
Ricinus communis agglutinin I; SILAC, stable isotope labeling by amino
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TNBC. As such changes might be associated with both
large-scale and more subtle changes in glycan compos-
ition, we developed a unique high-throughput lectin
microarray to enable multiplex characterization of cell
surface glycans that is capable of identifying a wide
range of differences in glycan composition [14].
With this array, we identified clear differences in the
lectin-binding patterns between TNBC cells that differed
in metastatic capacity (Figure 1). Further, as judged by
the order of the cells in the heat map (Figure 1e), the de-
gree of correlation among these multiplex lectin-binding
patterns essentially followed the metastatic capacity of
the cells. That is, the cells with the most similar lectin-
binding patterns were also most similar to each other in
metastatic capacity. Thus, widespread, subtle changes in
cell surface glycosylation accompany the progression of
the metastatic capacity of these cells. While the func-
tional implications of these changes remains to be fur-
ther investigated, this observation raises the possibility
to use such multiplex lectin-binding patterns in future
diagnostic applications, and perhaps identify subtle
changes in cell surface glycan composition prior to the
manifestation of significant metastases in these patients.
Yet an additional benefit of this means of characteriza-
tion is the ability to identify specific lectins whose ex-
tents of binding might also directly correlate with
metastatic capacity. Indeed, we found that the extent of
binding of a single lectin, RCA-I, alone, was proportional
to the metastatic potential of these cells. This result was
also confirmed with patient-derived tissue microarrays
(Figures 3 and 4). Hence, RCA-I tissue staining alone
could serve as a potential index to quickly assess the risk
of metastasis of TNBC patients and also predict the out-
come of TNBC patients.
However, somewhat surprising, we also found that
RCA-I might also prove useful in future studies aimed at
understanding basic steps in TNBC metastasis, since its
binding specifically and significantly inhibited TNBC in-
vasion in the cell mobility assays. It is known that me-
tastasis, especially hematogenous metastasis, is triggered
by cell-cell interactions between cancer cells and vascu-
lar endothelial cells, followed by migration across the
vascular wall, invasion into target tissues, and finally for-
mation of the secondary tumor [34]. We found that
RCA-I specifically inhibited cell adhesion more signifi-
cantly than invasion or migration, with marked inhib-
ition observed within 1 hr. Previously, there has been a
great deal of focus on the migration and invasion steps
of breast cancer cells metastasis [35]. However, the ini-
tial adhesion events of cancer cells are also clearly im-
portant, as they lead to the activation of cell surface
receptors, release of chemokines, and are possibly asso-
ciated with the formation of permissive metastaticmicroenvironment [36]. Our results thus implicate RCA-
I-specific glycans as playing a critical role in this import-
ant first step, and suggest that future studies with RCA-I
could provide more detailed understanding of its under-
lying molecular mechanisms. Further, with such an inhibi-
tive effect on TNBC metastasis, such studies will also
enable greater exploration of whether RCA-I could also be
developed into useful therapy.
We also identified POTEF as a binding partner of
RCA-I, and further, that it exhibits significantly altered
extents of galactosylation in high/low metastatic TNBC
cells. Although there is presently little known about this
protein, most members of the POTE family are believed
to be located on the plasma membrane and co-localize
with actin filaments [37]. As is well known, actin fila-
ments play important roles in cell motility and the estab-
lishment and maintenance of cell junctions to the
extracellular matrix (ECM). Hence, this connection with
actin may be related to the effects of RCA-I in cell inva-
sion. Further, this identification, together with the ob-
served effects of RCA-I in cell adhesion, suggest that the
enhanced galactosylation of POTEF may be a contribut-
ing factor in this early step of TNBC metastasis.
Finally, we note that the procedures established here
to study metastasis-associated cell surface glycans in
TNBC are general and could be easily adopted for the
study of other types of tumors. Lectin microarrays are
an emerging technology that derived from well-established
protein microarray techniques, which are capable of pro-
viding glycome-wide analyses of cell surfaces for rapid
comparative screenings or more in-depth characteriza-
tions of the individual lectin-binding characteristics
[38,39]. We thus expect further application of this tech-
nology will enable a greater understanding of the role of
altered glycosylation in carcinogenesis and in other altered
cellular states.
Conclusions
Using a high-density lectin microarray, we screened six
TNBC cells of different metastatic abilities from a com-
mon progenitor and found several lectins that exhibited
altered bindings to these cells. In particular, a single-
terminal galactose-binding lectin RCA-I showed a posi-
tive correlation with the metastatic capacity of these
TNBC cells. Furthermore, FCM and immunofluores-
cence experiments using the same lectins validated the
observations from the lectin microarray. The correlation
between the extent of RCA-I binding and TNBC pro-
gress was also confirmed by both TNBC-only and overall
breast cancer patient-derived tissue microarrays. Not-
ably, the Kaplan-Meier curves from these tissue arrays
showed a high correlation between RCA-I staining and
the outcomes of TNBC patients. Thus, RCA-I could
serve as a diagnostic biomarker to predict the risk of
Zhou et al. Breast Cancer Research  (2015) 17:36 Page 13 of 14TNBC metastasis. Importantly, we discovered, for the
first time, that RCA-I could inhibit TNBC cell adhesion,
migration, and invasion to a degree that correlated with
their metastatic abilities. We speculate that RCA-I inhib-
ited the motilities of TNBC cells by blocking the
metastasis-associated surface glycans and, hence, RCA-I
might also have therapeutic potential. Finally, we identi-
fied a single membrane glycoprotein, POTEF, in the
RCA-I-enriched fraction of proteins that exhibited mark-
edly enhanced galactosylation in highly metastatic TNBC
cells. Further investigation of this poorly understood
membrane protein is needed to more fully understand
its role in TNBC metastasis.
Additional files
Additional file 1: Figure S1. The summary of bindings of lectins with
six TNBC cell lines The bindings of all 91 lectins on the microarray and six
TNBC cells of different metastatic abilities are summarized and displayed
by fluorescent signal intensities.
Additional file 2: Figure S2. The verification of RCA-I binding to TNBC
and non-TNBC cell lines. (a) FCM analysis of the positive rates of RCA-I
binding to eight TNBC cells and two non-TNBC cells. (b) RTCA analysis shows
the relative invasion abilities of five TNBC cells and two non-TNBC cells.
Additional file 3: Figure S3. The representative pictures of IHC assays
of TNBC and non-TNBC tissue samples using RCA-I TNBC (red frame) and
non-TNBC (green frame) tissue samples stained by RCA-I were displayed
according to different T and N grades.
Additional file 4: Figure S4. Cell aggregation and viabilities of TNBC
cells treated with RCA-I. (a) Average cell volumes of the TNBC cell lines
4175, SCP28 and SCP6 treated with RCA-I of different concentrations.
(b) Cell index which reflexes cell viabilities of TNBC cell lines 4175, SCP28
and SCP6 incubated with RCA-I of 0, 1.0, 2.5, 5.0 μg/ml, were detected by
RTCA system.
Additional file 5: Figure S5. Cell invasions of TNBC cells with WFA of
different concentrations The invasion rates of the TNBC cell lines 4175, SCP28
and SCP6 treated with lectin WFA of the same concentration as RCA-I.
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